Chordate Medical AB
Henrik Rammer is an experienced board member and investor with a diverse background in the medical device and finance sectors. Currently serving on the boards of MYoroface AB and Chordate Medical AB, Rammer has a focus on innovative healthcare solutions, including treatments for orofacial disorders and neuromodulation for migraine relief. Previous roles include board positions at AddBio AB, SensAbues, and Paradiset, as well as co-founding RRM Capital Partners. Rammer has held influential positions at Axcel and Triton Partners, specializing in investment strategies, and was a co-founder and CFO of Allocation Network GmbH. Rammer holds a Bachelor of Science degree in Economics from The London School of Economics and Political Science and a Baccalauréat in Economics from Lycée Albert 1er in Monaco.
This person is not in the org chart
This person is not in any teams
Chordate Medical AB
Chordate Medical is a medical technology company that has developed, patented and CE-marked a neuromodulation and drug-free treatment technology for chronic migraine and chronic nasal congestion (rhinitis), Ozilia™ Migraine. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm.